David Sallman, MD, is an assistant member of the Department of Malignant Hematology at the H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. Dr Sallman undertook his medical degree at the University of South Florida College of Medicine, Tampa, FL, before completing his residency in internal medicine at Massachusetts General Hospital, Boston, MA. He went on to complete a hematology-oncology fellowship at H. Lee Moffit Cancer Center. His work has been recognized with numerous awards across his qualifying years, including the 2010 Florida American College of Physicians Award, 2015 Alpine Oncology Foundation Young Investigator Award, and the 2016 Moffitt Institutional Trainee Award. In 2015, Dr Sallman was named as an Evans Fellow of the MDS Clinical Research Consortium. Focused on treating myelodysplastic syndromes (MDS) and leukemia, Dr Sallman has a significant record of publication in top peer-reviewed journals including Leukemia and Haematologica.
Speaking on novel targeted agents in AML/MDS
Dr Sallman’s research interests surround the development of novel targeted therapeutic agents for use in MDS and acute myeloid leukemia (AML). His work aims to identify genetic drivers in these myeloid malignancies and understand their impact, in order to improve prognostication and form the basis for development of targeted therapies and personalized treatment strategies.